| Market Capitalization (Millions $) |
147 |
| Shares
Outstanding (Millions) |
15 |
| Employees |
14 |
| Revenues (TTM) (Millions $) |
6 |
| Net Income (TTM) (Millions $) |
-17 |
| Cash Flow (TTM) (Millions $) |
-9 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Atara Biotherapeutics Inc is a clinical-stage biopharmaceutical company that focuses on developing novel therapeutics to treat serious diseases, particularly rare and debilitating conditions. The company harnesses the power of the immune system to improve outcomes for patients with cancer, autoimmune diseases, and viral infections.
Atara Biotherapeutics specializes in developing T-cell immunotherapies, which involve modifying a patient's own immune cells to recognize and attack disease cells. One of the company's flagship product candidates is tabelecleucel (formerly known as ATA129), which is a T-cell immunotherapy being evaluated for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disorders (EBV+ PTLD) in patients who have undergone solid organ transplantation.
The company's pipeline also includes other potential therapies, such as ATA188, which is being developed for the treatment of progressive multiple sclerosis, as well as ATA3271, a mesothelin-targeted CAR T-cell therapy for the treatment of solid tumors.
Atara Biotherapeutics' mission is to transform the lives of patients with severe and life-threatening diseases by leveraging the potential of immunotherapy. They strive to bring innovative therapies to market to address significant unmet medical needs and improve patient outcomes.
Company Address: 1280 Rancho Conejo Boulevard Thousand Oaks 91320 CA
Company Phone Number: 623-4211 Stock Exchange / Ticker: NASDAQ ATRA
|
1.16% 